On September 10, 2020, Korro Bio, Inc., a biotech start-up founded in 2018, announced a $91.5 million Series A financing to advance its novel platform for precise, single-base, RNA editing to modulate protein function for therapeutic applications. The financing was led by Wu Capital with participation from current investors Atlas Venture and New Enterprise Associates. Wilson Sonsini Goodrich & Rosati advised Wu Capital in the financing.

The financing enables Korro to advance its lead program to IND filing and establish a broad portfolio of innovative RNA editing therapies. Korro’s proprietary platform, OPERA (Oligonucleotide Promoted Editing of RNA), harnesses the body’s natural base editing system to make targeted edits to a single RNA base. OPERA can repair disease-causing mutations at the RNA level, in addition to creating therapeutically beneficial versions of proteins to improve patient outcomes.

The Wilson Sonsini team advising Wu Capital includes partners Dan Koeppen and Joshua Gruenspecht, and associates Kassandra Castillo and John Lynch.

Please see Korro Bio’s press release for more information.